ArticleFrontiers in cell and developmental biology2025
Molecular subtyping and functional characterization of gastric cancer using arginine metabolism-related genes.
Article in Frontiers in cell and developmental biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Integrating multiple omics and machine learning to reveal the prognostic value of endoplasmic reticulum stress geneTranslational cancer research · 2026Article
- CCA-1.1 Destabilizes MYC proteins to induce irreversible anti-proliferative effects in hepatocellular carcinoma.Medical oncology (Northwood, London, England) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Gastric cancer (GC) remains one of the most lethal malignancies worldwide due to its substantial heterogeneity, necessitating improved therapeutic strategies and prognostic tools. Recent studies have implicated dysregulated arginine metabolism in GC pathogenesis; however, its metabolic characteristics and clinical prognostic value are not fully understood. Methods: GC samples were classified into three molecular subtypes based on the expression profiles of arginine metabolism-related genes (ArMGs). Prognostic ArMGs were identified within each subtype, and a cross-dataset prognostic model was developed to assess its predictive value. The associations of the model with anti-tumor immunotherapy, tumor immune microenvironment, signaling pathways, and gene expression patterns were further explored. Key candidate genes were validated using quantitative polymerase chain reaction (qPCR) in GC tissues and cell lines, and their biological functions were investigated through functional assays. Results: Consensus clustering of nine ArMGs stratified GC into three molecular subtypes: C1, C2, and C3. A prognostic prediction model for GC was constructed using differentially expressed genes among the subtypes and seven key prognostic genes: TMEM171, SLC5A1, DEGS2, MGP, C7, HMGCS2, and CREB3L3. The model demonstrated varying sensitivities to anti-tumor immunotherapy and showed strong correlations with immune-related tumor markers, the tumor immune microenvironment, and multiple signaling pathways. Among the ArMGs, ODC1 and ALDH18A1 were identified as critical contributors to GC. qPCR confirmed their elevated expression in GC tissues and cell lines. Silencing these genes significantly reduced GC cell proliferation, colony formation, and invasion. Conclusion: This study comprehensively characterized the molecular features of ArMGs in GC and developed a robust, validated prognostic prediction model. The findings offer new molecular insights for predicting patient outcomes and guiding personalized therapeutic strategies in GC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.